CUA Educational Content

PSMA PET/CT Beyond the Images: The Imager’s and Clinician’s Perspective

EDITORIAL COMMITTEE: Bobby Shayegan, Katherine Zukotynski, Frédéric Pouliot, Stefano Fanti

By the end of this program, participants will be able to:

  • Describe the several PSMA-targeting tracers and PET/CT technology
  • Describe the accuracy of PSMA-PET/CT for staging and re-staging prostate cancer based on best prospective studies
  • Understand the basis of PSMA radioligand therapy and the trials in metastatic prostate cancer


This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Urological Association. You may claim a maximum of 1 hour of credit.


This program has received financial support from The ICPO Foundation, Oncidium Foundation, and Advanced Accelerator Applications: A Novartis Company in the form of an educational grant